Inflammatory breast cancer: experience of center Mohammed VI for the treatment of cancers

A. Ibrahim Khalil 1, H. Kaiss 2, F. Qachach 2, B. Bilal 2, S. Majdoul 2, S. Belkheiri 2, K. Bendahhou 2, N. Benchakroun 3, A. Benider 3

1. Registry Cancers Of Great Casablanca - Morocco
2. Center Mohammed VI for treatment of cancers, CHU Ibn Rochd Casablanca - Morocco

Background

Inflammatory breast cancer (IBC) is a rare but particularly aggressive form. This is a subtype locally advanced to the TNM classification of breast cancer. It accounts for about 1 to 5% of all breast cancers. Its clinical form and its etiology remains unknown.

The objective of this study was to describe the epidemiological, clinical, biological and therapeutic inflammatory breast cancer in center Mohammed VI for the treatment of cancer CHU Ibn Rochd Casablanca.

Patients and methods

This is a descriptive transversal study, from January 2010 to December 2015, including all cases of inflammatory breast cancer, treated the center. Data were collected from medical records and the statistical analysis by software R.

Results

A total of 57 patients had a CSI supported in the center with an average of 50.2 ± 11.8 years with extremes (32-90 years), 22.8% of cases were using oral contraceptives, 17.5% were menopausal at diagnosis, only one case had a family history of breast cancer. 7.0% were bilateral and right tumor laterality was in 49.1% of cases. Clinical signs were in 82.5% of breast swelling, mastodynie, redness, orange peel, and retraction of the nipple were respectively 36.8%, 29.8%, 19.3% and 22.8% of cases. The most common histological type was invasive ductal carcinoma in 82.5% of cases. Histological grade SBR 3 was the most frequent in 47.4% of cases. A positive estrogen receptor was observed in 59.5% of cases and progesterone in 40.5% of cases. Her2 is overexpressed in 50.0% of the cases, 20.7% of cases were triple negative.

All cases had received neoadjuvant chemotherapy, surgery, adjuvant chemotherapy, radiotherapy, hormone therapy and targeted therapy were recommended respectively 8.8%, 1.8%, 8.8%, 3.5%, 3.5% of cases. The overall survival at 5 years of the CSI is 27.0% in our series.

Conclusion

Inflammatory breast cancer is less frequent in our center but with very aggressive characteristics. Further investigations are needed to better explain this tumor type.

Keywords: breast cancer inflammatory, epidemiology, clinical, histology, therapy Survival.